[go: up one dir, main page]

WO2010027370A9 - Compositions and methods for the treatment of solid tumor cancers - Google Patents

Compositions and methods for the treatment of solid tumor cancers Download PDF

Info

Publication number
WO2010027370A9
WO2010027370A9 PCT/US2008/075761 US2008075761W WO2010027370A9 WO 2010027370 A9 WO2010027370 A9 WO 2010027370A9 US 2008075761 W US2008075761 W US 2008075761W WO 2010027370 A9 WO2010027370 A9 WO 2010027370A9
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
solid tumor
compositions
tumor cancers
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/075761
Other languages
French (fr)
Other versions
WO2010027370A1 (en
Inventor
Ronald J. Buckanovich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
University of Michigan Ann Arbor
Original Assignee
University of Michigan System
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System, University of Michigan Ann Arbor filed Critical University of Michigan System
Publication of WO2010027370A1 publication Critical patent/WO2010027370A1/en
Publication of WO2010027370A9 publication Critical patent/WO2010027370A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to compositions and method for the treatment of solid tumor cancers. For example, the present invention provides therapeutic antibodies, including anti- CD52 immunoglobulin such as alemtuzumab, for the treatment and prevention solid tumor cancers, including ovarian cancer.
PCT/US2008/075761 2008-09-08 2008-09-10 Compositions and methods for the treatment of solid tumor cancers Ceased WO2010027370A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9522408P 2008-09-08 2008-09-08
US61/095,224 2008-09-08

Publications (2)

Publication Number Publication Date
WO2010027370A1 WO2010027370A1 (en) 2010-03-11
WO2010027370A9 true WO2010027370A9 (en) 2010-07-22

Family

ID=41797360

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/075761 Ceased WO2010027370A1 (en) 2008-09-08 2008-09-10 Compositions and methods for the treatment of solid tumor cancers

Country Status (1)

Country Link
WO (1) WO2010027370A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE386748T1 (en) * 2003-12-19 2008-03-15 Charite Universitaetsmedizin USE OF CD52 ANTIGEN LIGANDS TO TREAT SOLID TUMORS AND BONE CANCER DISEASES

Also Published As

Publication number Publication date
WO2010027370A1 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
HK1206040A1 (en) Anti-egfr antibodies and uses thereof
WO2012078688A3 (en) Humanized antibodies to liv-1 and use of same to treat cancer
HK1254880A1 (en) Anti-pd-1 antibodies and uses thereof
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
WO2012165815A3 (en) Nano-vehicle derived from tumor tissue, and cancer vaccine using same
WO2008079988A3 (en) Quinazolines for pdk1 inhibition
WO2011094335A3 (en) Microrna signatures predicting responsiveness to anti-her2 therapy
MY150756A (en) Tumor theraphy with an anti-vegf antibody
WO2011082270A3 (en) Substituted imidazopyridinyl-aminopyridine compounds
WO2011082273A3 (en) Substituted pyrrolo-aminopyrimidine compounds
HK1253049A1 (en) Glycan-interacting compounds and methods of use
EA201201000A1 (en) METHODS OF TREATMENT OF COLORECTAL CANCER
WO2011082267A8 (en) Substituted triazolo-pyrazine compounds
AU2016219704A1 (en) Anti-Notch1 antibodies
WO2007053573A3 (en) Treatment of cancer with sorafenib
EP4183806A3 (en) Glycan-interacting compounds and methods of use
ZA202006318B (en) Anti-dll3 antibodies and uses thereof
WO2011123678A3 (en) Substituted benzo-pyrido-triazolo-diazepine compounds
WO2008110379A3 (en) Monoclonal antibodies for treatment of cancer
WO2015054600A3 (en) Glycan-interacting compounds and methods of use
WO2010032011A8 (en) Anti-fungal therapy
BR112013003257A2 (en) humanized egfr antibodies.
WO2009051957A3 (en) Antibodies to irem-1
WO2011082268A3 (en) Substituted naphthalenyl-pyrimidine compounds
WO2013052108A3 (en) Methods and compositions for the treatment and diagnosis of ovarian cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08821790

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08821790

Country of ref document: EP

Kind code of ref document: A1